Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Peter Krull, director of Earth Equity Advisors, discusses why he's bullish on renewable energy and shares his top clean ...

A new study published in the Journal of Autism and Developmental Disorders suggests that the ability to comprehend complex ...

Now that we’re a few weeks removed from the official launch of the Magic: The Gathering Final Fantasy Universes Beyond […] ...

How does market reflexivity amplify volatility? Learn why self-reinforcing feedback loops between investor belief and price action create explosive crypto bubbles and crashes.

Elon Musk is very optimismi about AI + robotics leading to an age of extreme abundance. He sees a Star Trek future and not ...

Blockchain security firm CertiK has recently released pivotal updates that shed light on regulatory shifts and technical ...

When short sellers are betting heavily against a company, shareholders should exercise caution. At the top of the list is ...

The strategic insertion of the past is no longer incidental in Bollywood films. It has become a deliberate trope in ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

Ahead of the MTG Lorwyn Eclipsed January 2026 launch, Wizards of the Coast revealed a wealth of cards that players can expect ...

Insilico目前拥有超过40种人工智能研发的药物，用于治疗癌症、肠道疾病和肾脏疾病等。而且，其研发方法正在不断推广。据预测，2025年至2030年间，该领域的年度投资额将从38亿美元增至152亿美元。